Challenges and threats

Read full text Summarise with VIRAT
Authors: Diogo Alexandre Martins-Branco, Wim Demey, Emad Shash, Evandro de Azambuja
Cited by: 0
References: 19

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Abstract Optimal breast cancer research requires collaboration between many stakeholders: scientists, clinicians, trialists, statisticians, the pharmaceutical industry, and most importantly patients and their representatives. The design of studies must be done more in accordance with patients’ needs and to optimize equity and diversity in access to innovation. Efforts should be made to design inclusive registration trials or generate evidence on unmet-need clinical settings such as subpopulations of ethnic/racial minorities, younger or older patients, male breast cancer patients, or patients with brain metastases. Patient-centred translational research is an important component of clinical trials. Selected endpoints should be clinically relevant endpoints and adapted to the disease setting and to the investigational therapeutic area. The current gap between innovation and clinical practice/use must be closed.

Fields of Study & Subjects

Breast Cancer Treatment Studies Statistical Methods in Clinical Trials Ethics in Clinical Research

Publication details

Journal / source
Oxford University Press eBooks
Pages
320–326
Publication date
1 March 2026
Language
EN
Document type
Book chapter